Clinical Trials Browser

Phase 2 × Glioblastoma × Combined Modality Therapy × Clear all

NCT00805961 2021-12-08

RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM

Phase 2 Completed

68 enrolled 8 charts

Glioblastoma